Redx Pharma Share Discussion Threads

[760il] 23/3/2016 18:20

Keep grinding my baby

Buy low sell high is the motto

[760il] 23/3/2016 15:47

Nearly 1 year since ipo.

[760il] 23/3/2016 15:43

Keep grinding


slowly and harder

[mach100] 01/3/2016 12:23

This one is looking a bit sickly. A pity really as it has an interesting pipeline. Some news on MRSA might give it a fillip but its slow death spiral from 100p in a short space of time is quite painful to watch.

[sharesoc] 16/10/2015 16:05

We have one of our growth company seminars near Manchester on the 28th October with REDX Pharma presenting, more details at:

[sharesoc] 16/10/2015 16:05

We have one of our growth company seminars near Manchester on the 28th October with REDX Pharma presenting, more details at:

[proactivest] 06/10/2015 15:04

Video interview with CEO Murray



Neil Murray, chief executive of Redx Pharma (LON:REDX), says there are strong commercial returns available in the antibiotics market for the “right drug with the right profile”.

The company is working on a new compound designed to tackle MRSA, which began pre-clinical testing in the second half of this year and is advancing well.

Other areas of focus for the business include oncology (bone tumours, skin, brain and blood cancers).

[bad robot] 05/8/2015 11:11

My target of 500p remains

[bad robot] 20/7/2015 14:08

another one BR baby rocketing into the strastosphere

[rafboy] 22/6/2015 11:18

No comments on the half yearly results! Well, cash position is strong after placing and looks to me to be enough for 18 months or longer. Anyone else have any views?

[rafboy] 15/6/2015 15:59

Think Redx is holding up very well and the share price has even risen a little today. I am quite excited about prospects here and I like the idea of working alongside the NHS.

MRSA is such a problem for hospitals and Redx do seem to be on to something. Anyway added a few today so putting my money where my mouth is so to speak.

[rafboy] 05/6/2015 15:53

Looks like back to normal volume day until next news. Still, more buys than sells so happy to head north slowly.

[mirabeau] 04/6/2015 05:52

Five top European biotech SMEs to be rewarded by Commissioner Carlos Moedas and EuropaBio

June 3, 2015 by IPFrontline in Intellectual Property Management

The five shortlisted SMEs are:

Healthcare or Red Biotech Category

Prize sponsored by Deerfield Management Company

'Based in the UK, Redx Pharma is focused on the development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer and infection and immunology. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 13 proprietary, drug programs. Five programs have achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, and solid and liquid tumours.'

[letmepass] 02/6/2015 22:50

Not even at clinical stage one. When it drops will be difficult to sell and it will.

[seconduser] 02/6/2015 20:09

More news- this help from the Daily Mail??



Have read right to the end to get the relevant bit:

"studies have found your toothbrush can also harbour dangerous bacteria such as staphylococcus aureus, which is associated with MRSA infection."

[whitebicycle] 02/6/2015 19:14

There is a bit more flesh to the announcement. Didn't think it would kick up again at the end as the spread widened to 3p.
Massive potential now there is news flow.

[talkingtrades] 02/6/2015 14:28

Not trying to ramp but as well as this I own OPTI.Very hot sector .Take a look.

[seconduser] 02/6/2015 14:18

TT If you want more info then LSE seems to be the main BB for this share. Good luck.

[talkingtrades] 02/6/2015 14:05

Hi just purchased here.Potential looks good after initial research.

[seconduser] 02/6/2015 11:54

Bit surprised by rather muted response to RNS.

Proactive Investor:

"The need for new drugs to tackle resistant bacteria is pressing.

Ten million could die, while a massive £25bn has to be poured into the healthcare system to fight the rear-guard against infection, according to a report by former Goldman Sachs economist Jim O’Neill.

He was commissioned by Prime Minister David Cameron to look at the threat posed by a lack of effective treatments for infection such as MRSA, c.difficile and E.coli."